Gilde Healthcare Partners, the Dutch private equity firm which has Royal Philips as an investor, and Forbion Capital Partners, the former corporate venturing unit of ABN Amro, have helped Euronext-listed healthcare company Amsterdam Molecular Therapeutics raise €2.5m ($3.2m).
Forbion and Gilde were joined by venture firm Advent Venture Partners injecting crisis funds into the company on December 30, after it announced it was in negative equity last month. The three were all previous investors in the gene therapy company, which listed in 2007.
The additional funds "do not eliminate the company’s negative equity position" Amsterdam Molecular Therapeutics said, but "would give it additional flexibility".
Since December 31 Amsterdam Molecular Therapeutics’s share price has risen 4.1% giving it a market capitalisation of €9m.
At the time of its initial public offering AMT was backed by Advent, Forbion, Gilde, Credit Agricole Private Equity, the unit of the French bank, and healthcare organisations Essential Medical Treatments as well as Amsterdam Medical Center. The company raised €22m in its series A financing in 2006. The company was founded in 1998.
Philips said in August 2010 it was a cornerstone in a €200m fund being raised by Gilde Healthcare Partners and Janke Dittmer joined Gilde from the Dutch electronics company in 2011.